DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aricept (Donepezil Hydrochloride) - Summary

 
 



ARICEPT SUMMARY

ARICEPT® (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase.

ARICEPT® is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.


See all Aricept indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aricept (Donepezil)

ARICEPT (Donepezil) effective for severe Alzheimer's disease
Source: The Doctors Lounge - Neurology
Donepezil reverses some aspects of cognitive deterioration seen in severe Alzheimer's disease.

Study demonstrated clinically meaningful and statistically significant improvement of agitation in patients with Alzheimer's disease
Source: Anxiety / Stress News From Medical News Today [2014.10.16]
Avanir Pharmaceuticals, Inc. has announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014...

Laying siege to beta-amyloid, the key protein in Alzheimer's disease
Source: Huntingtons Disease News From Medical News Today [2014.10.06]
The peptide - a small protein - beta-amyloid is strongly associated with Alzheimer's disease; however, researchers are still looking for unequivocal proof that this peptide is the causal agent of the...

Memory and Alzheimer's disease
Source: Schizophrenia News From Medical News Today [2014.09.03]
Research by Dr. Sylvain Williams shows that the flow of activity in the hippocampus, a brain region essential for memory, is actually bidirectional, rather than just unidirectionalA study just...

Protein implicated in Alzheimer's disease has important treatment potential in genetic form of epilepsy
Source: Epilepsy News From Medical News Today [2014.08.16]
Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe...

more news >>

Published Studies Related to Aricept (Donepezil)

Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued

Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. [2011.11]
OBJECTIVES: To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair... CONCLUSION: Participants randomized to donepezil had no significant improvement in delirium presence or severity but experienced more side effects. Overall, sufficient evidence was not found from this pilot study to warrant a definitive Phase III trial. (c) 2011, Copyright the Authors Journal compilation (c) 2011, The American Geriatrics Society.

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. [2011.08]
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer's disease (AD)...

Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. [2011.05]
BACKGROUND: Our aim was to assess the safety, tolerability, and efficacy signal of early donepezil administration with regard to enhancing recovery in a diverse acute ischemic stroke population... CONCLUSIONS: Adjuvant donepezil therapy initiated within 24 hours of acute ischemic stroke was safe and tolerated at 5 mg/day to 10 mg/day. The study met a priori criteria to move forward with a randomized clinical trial. Copyright (c) 2011 National Stroke Association. Published by Elsevier Inc. All rights reserved.

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. [2011.05]
CONCLUSIONS: In this exploratory study, SB-742457 and donepezil were associated with improvements in global function. Treatment effect on cognition for both SB-742457 and donepezil was smaller than those previously observed in previous clinical studies with donepezil. Copyright (c) 2010 John Wiley & Sons, Ltd.

more studies >>

Clinical Trials Related to Aricept (Donepezil)

Aricept to Improve Functional Tasks in Vascular Dementia [Recruiting]
Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer’s Disease [Completed]
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer’s disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer’s disease.

Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person’s memory to work better.

Donepezil and Memantine in Moderate to Severe Alzheimer's Disease [Recruiting]
The trial will examine whether pharmacological treatment with donepezil, memantine or combination of memantine and donepezil is any better than a placebo (dummy) treatment in people with Alzheimer's disease who have reached the moderate to severe stage of illness. Using a double blind design, where neither the investigators nor participants know who is receiving which treatment, participants will be randomly assigned to one of these four treatment groups (donepezil and memantine, memantine only, donepezil only or placebo). In order to keep both the investigators and participants blind to drug allocation a double dummy design will be necessary. This means that each participant will receive 2 treatments − either an active form or placebo of each of the 2 study drugs.

Hypotheses are:

1. Patients with Alzheimer's disease (AD) who continue donepezil beyond the point of transition from moderate to severe dementia continue to show significantly less decline on ratings of cognitive function and activities of daily living over the following 12 months than those discontinuing donepezil.

2. Patients with AD who change to memantine therapy in place of donepezil at the point of transition from moderate to severe dementia show significantly smaller decline on ratings of cognitive function and activities of daily living over the following 12 months than those who receive placebo.

3. Patients given the combination of memantine and donepezil at the point of transition from moderate to severe dementia show significant additive or synergistic benefits on measures of activities of daily living and cognitive function after 12 months compared to those patients continuing on either drug as a single treatment.

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease [Recruiting]
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.

more trials >>

Reports of Suspected Aricept (Donepezil) Side Effects

Syncope (31)Electrocardiogram QT Prolonged (26)Convulsion (25)Drug Interaction (24)Fall (22)Altered State of Consciousness (21)Bradycardia (20)Dementia (19)Vomiting (19)Loss of Consciousness (18)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 9 ratings/reviews, Aricept has an overall score of 4.67. The effectiveness score is 5.56 and the side effect score is 6.44. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Aricept review by care giver of 69 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Alzheimers
Dosage & duration:   5g for one month rising to 10g (dosage frequency: daily) for the period of 3 months total - and on-going
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Only moderate improvements noted on the 5g dosage. Improvements much more noticeable at 10g - or after 30 days of taking medication. Less confusion, more awareness in social surroundings, more outward and positive in attitude.
Side effects:   So far no negative noted
Comments:   Take one pill in the morning. Also vitamin supplements (Multi-vitamin, brain-booster vitamin, and homo-cysteine level reducer)

 

Aricept review by care giver of 80 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Alzheimer's disease
Dosage & duration:   10 mg taken once daily for the period of 6 months
Other conditions:   hernia, teeth problems
Other drugs taken:   Tamasapan
  
Reported Results
Benefits:   We could not identify any benefits at all. The behavior and memory problems remained unchanged or worsened over time. Anxiety continued to increase and the dementia progressed systematically. Disorientation continued to increase and the patient became more and more difficult to manage. It appeared that irritability increased and the patient became more agitated more easily.
Side effects:   There was some indication that there was at least some increase nausa as well as some infrequent but increased bouts of diarrhea. There were a few episodes of vomiting, but it might be attributed to other factors for this one side effect. There was definitely increased insomnia as well as loss of appetite, but it can not be definitively stated that the drug alone contributed to these although it did occur after the drug was begun.
Comments:   The patient was given a daily dose. After transfer to a care facility, the regimentation in taking the dose was firmly set in place. Staff medical personnel on site did not observe any benefits, and as a result, after about 6 months the prescription was terminated. During the time the drug was used, there was a patient review every other week to ascertain whether there seemed to be any improvement in the patient. Memory tests were administered and one-on-one interviews were executed by medical personnel. The results of the memory testing showed no net improvement nor was there any identifiable changes that might be considered positive. Ultimately her psychiatrist in consultation with the family decided that the drug did not seem to provide any net gain.

 

Aricept review by care giver of 67 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   short term memory loss
Dosage & duration:   5 mg taken once for the period of once
Other conditions:   severe head pain, feel like throwing up
Other drugs taken:   welbutrin
  
Reported Results
Benefits:   none, only took one pill and found that the side effects do not warrant continued use.
Side effects:   severe head pain, feel like throwing up, felt lousy for 12 hours after taking first pill.
Comments:   Will not take pill again. The side effects of loosing a nights sleep, having severe head pain, and feeling like throwing up will result in not taking another pill as this drug does not agree with patient.

See all Aricept reviews / ratings >>

Page last updated: 2014-10-16

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014